Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2008 Nov 5;26(47):5899-904. doi: 10.1016/j.vaccine.2008.08.062. Epub 2008 Sep 17.

MeNZB vaccine and epidemic control: when do you stop vaccinating?

Author information

  • 1Toi Te Ora - Public Health, Bay of Plenty District Health Board, Tauranga, New Zealand. bjloring@yahoo.com

Abstract

New Zealand developed a strain-specific group B meningococcal vaccine to control an epidemic. Following a mass vaccination campaign of three doses to the population under 20 years of age, commencing in July 2004, the vaccine continued to be offered routinely as a four-dose schedule from 6 weeks of age. There is little international data on when to cease epidemic vaccination campaigns. The decision to stop using this vaccine needed to take into account a range of factors. These included epidemiology, vaccine effectiveness and duration of immunity, vaccine coverage, concomitant use with other vaccinations being added to the infant schedule, vaccine supply and cost-benefit criteria. This paper discusses these issues, along with the potential challenges for communication to both health professionals and the public.

PMID:
18804134
DOI:
10.1016/j.vaccine.2008.08.062
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center